SNTB2

Across TCGA pan-cancer cohorts, SNTB2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SNTB2 data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher SNTB2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SNTB2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, LAML, and MESO are the cancer types where SNTB2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.122	0.696	<.001	45	view →
LAML	DFS	Median	All	0.081	0.572	.003	12	view →
MESO	DFS	Median	III,IV	0.140	0.379	.033	9	view →
UCEC	DFS	Median	All	1.000	0.629	.026	8	view →
SKCM	DFS	Median	All	0.216	0.624	.001	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SNTB2–HNSC (DFS)

Open the HNSC breakdown →